Engineered lymphatic stroma model applications in central nervous system leukemia
Integrative Biology · 16.01.2026 · 18
DOI: 10.1093/intbio/zyag012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Integrative Biology, online erschienen am 11.06.2026. Verfasst von Jennifer H Hammel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Virginia Tech, 325 Stanger Street, Blacksburg, VA 24061, USA. Hauptthemen laut MEDLINE: Tissue Engineering, Central Nervous System Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 60 Literaturangaben.
Abstract (Originalsprache)
Central nervous system (CNS) involvement frequently occurs in acute lymphoblastic leukemia (ALL), but many questions remain about how leukemia cells access, persist in, and exploit the CNS. The CNS is protected by the meninges, which are fluid-filled membranes that surround the brain. Within the meninges, meningeal lymphatic vessels, located within the dura mater, drain cerebrospinal fluid to the deep cervical lymph nodes for immunosurveillance, providing a potential pathway for leukemia cells to enter or exit the CNS. Here, we utilized tissue engineered models of the meningeal lymphatics and lymph node stroma to probe how leukemia cells interact with these key microenvironments. We first demonstrated that standard-of-care chemotherapeutics can perturb the meningeal lymphatics, particularly lymphatic endothelial cells. Next, we showed that soluble factors from the meningeal lymphatics conferred a modest upward trend in leukemia cell growth, while soluble factors from the lymph node model under flow significantly promoted leukemia cell migration. Finally, we showed that leukemia cells migrate through the lymph node model under both static and flow conditions. Overall, we have demonstrated the feasibility of using engineered lymphatic models to study leukemia cell behavior in the CNS with the goal of expanding the available experimental platforms for understanding CNS metastasis and relapse. Insight Box Leukemia commonly infiltrates the central nervous system (CNS), requiring intensive CNS-directed therapies that are often ineffective and cause both acute and long-term toxicities, especially in pediatric patients. The meningeal lymphatics and the deep cervical lymph nodes constitute a pivotal axis in CNS immunity, facilitating drainage of fluid and waste, and enabling peripheral immune surveillance in response to CNS-derived signals. Here, we employ in vitro models of the meningeal lymphatics and lymph node stroma to examine their crosstalk in influencing leukemia cell growth and migration. These engineered platforms serve as valuable tools for uncovering mechanistic insights into the meningeal-lymph node axis in the context of CNS-leukemia relapse.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Virginia Tech, 325 Stanger Street, Blacksburg, VA 24061, USA.
- Fralin Biomedical Research Institute at Virginia Tech, 4 Riverside Circle, Roanoke, VA 24016, USA.
- Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Minnesota, 2450 Riverside Ave, Minneapolis, MN 55454, USA.
- Masonic Cancer Center, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA.
Zitieren
APA
Hammel, J. H., Murphy, H. E., Oyediran, K. O., Gordon, P. M., & Roberts, L. M. (2026). Engineered lymphatic stroma model applications in central nervous system leukemia. Integrative Biology, 18. https://doi.org/10.1093/intbio/zyag012
Vancouver
Hammel JH, Murphy HE, Oyediran KO, Gordon PM, Roberts LM. Engineered lymphatic stroma model applications in central nervous system leukemia. Integrative Biology. 2026;18. doi:10.1093/intbio/zyag012
BibTeX
@article{Hammel2026,
author = {Hammel, Jennifer H and Murphy, Hailey E and Oyediran, Khadijat O and Gordon, Peter M and Roberts, L Monet},
title = {Engineered lymphatic stroma model applications in central nervous system leukemia},
journal = {Integrative Biology},
year = {2026},
volume = {18},
doi = {10.1093/intbio/zyag012}
}
EUVIMED